For how we live.
Kidney disease is usually silent until it is advanced, and most of it traces to diabetes and high blood pressure. Controlling those two, and getting tested, is the highest-yield protection — not kidney superfoods.
European hypertension specialists found only two wrist-cuff blood pressure watches with validation studies done to established protocols. A sleep group ran a Galaxy Watch against two nights of polysomnography.
A 2023 network meta-analysis of 270 trials ranked isometric exercise first for lowering resting blood pressure. Two 2026 analyses, using ambulatory monitoring and a larger trial set, rank it among the weakest.
In people who already have kidney disease, cutting salt reduced albuminuria by about 36% and lowered blood pressure. High salt also blunts standard kidney-protecting drugs — though long-term outcome trials are missing.
Global mean intake was 4,278 mg a day in 2021 against a recommended limit under 2,000. A week of low-sodium eating moved blood pressure in most people; a five-year trial of salt substitute cut strokes.
American guidelines call 130/80 stage 1 hypertension. European ones call the same reading elevated blood pressure and not yet disease. The measurement did not change. The label did.
After four weeks, the comorbid-insomnia group's blood pressure fell 20 points more than the apnea-only group. The finding flips the usual framing of COMISA as simply a worse-outcomes phenotype.
In 377 patients, hypoxic burden — a metric combining how often, how deep, and how long oxygen drops — tracked with abnormal nighttime blood pressure patterns where conventional measures didn't.
A February scientific statement declines to recommend the category for clinical decisions. Six weeks earlier, a journal retracted a validation study of a popular consumer model.
The FDA's revised general wellness policy lets non-invasive devices infer blood pressure, glucose and other physiologic parameters. The regulated line is no longer the measurement — it is the sentence next to it.
A meta-analysis of pedometer, tracker and smartwatch interventions lasting 12 to 48 weeks found no significant change in systolic or diastolic pressure — nor in weight, glucose or HbA1c.
Applying prevalence figures to UN population data yields 852 million adults with insomnia. Only 31 of 237 countries had a usable national estimate of their own.